The Use of COVID-19 Vaccines in Patients with SLE.
Wei TangYevgeniya GartshteynEdd RickerSean InzerilloShane MurrayLeila KhaliliAnca D AskanasePublished in: Current rheumatology reports (2021)
Patients with SLE have worse immune responses following SARS-CoV-2 vaccination than healthy controls. The efficacy of the COVID-19 vaccines seems to be further reduced by immunosuppressive medications, such as glucocorticoids (GC), methotrexate (MTX), mycophenolate/mycophenolic acid (MMF), and rituximab (RTX). However, these data do not substantiate that AIIRD patients are at greater risk of disease flares or have a higher incidence of side effects following vaccination. There is no significant safety concern for the use of COVID-19 vaccines in patients with AIIRD. The benefits of vaccination far outweigh the risks in patients with AIIRD, including SLE. More data are needed to determine the necessity of a booster vaccine dose and appropriate adjustment of immunosuppressants around the administration of vaccine.
Keyphrases
- sars cov
- systemic lupus erythematosus
- coronavirus disease
- respiratory syndrome coronavirus
- disease activity
- immune response
- end stage renal disease
- electronic health record
- newly diagnosed
- ejection fraction
- big data
- chronic kidney disease
- risk factors
- high dose
- diffuse large b cell lymphoma
- peritoneal dialysis
- toll like receptor
- risk assessment
- inflammatory response
- low dose
- machine learning
- dendritic cells
- hodgkin lymphoma
- chronic lymphocytic leukemia
- simultaneous determination